



Radius Health, Inc.
Investor Relations Department
950 Winter St, North Building 1st Floor
North Building 1st Floor
Waltham, MA 02451
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: RDUS

Last Trade:	29.62
Trade Time:	4:00 PM ET Dec 13, 2017
Change:	0.04 (+0.135%)
Day Range	28.65 - 30.10
52-Week Range	24.66 - 49.16
Volume	944,208

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius c... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Dec 11, 2017

[Fractured Truth Campaign Wins Bronze Pearl Award for Content Marketing Excellence in the Healthcare/Pharmaceutical Industry](#)

Dec 7, 2017

[Radius Investigational Drug Elacestrant \(RAD1901\) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium](#)

Dec 4, 2017

[Radius Health Announces Five Presentations on elacestrant \(RAD1901\) at the San Antonio Breast Cancer Symposium \(SABCS\)](#)

Nov 27, 2017

[Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635\(c\)\(4\)](#)

Nov 27, 2017

[Radius Health Announces Commercial Leadership Changes with Appointment of Joseph Kelly as Senior Vice President of Sales and Marketing, and Promotion of Amanda Mott to Senior Vice President of Market Access](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Feb 24, 2017

[Annual Report \(10-K\)](#)

Apr 21, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 2, 2017

[Quarterly Report \(10-Q\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)

May 2, 2017

[Quarterly Report \(10-Q\)](#)